Clinical Study

Efficacy of Subantimicrobial Dose Doxycycline for Moderate-to-Severe and Active Graves’ Orbitopathy

Miaoli Lin, Yuxiang Mao, Siming Ai, Guangming Liu, Jian Zhang, Jianhua Yan, Huasheng Yang, Aimin Li, Yusha Zou, and Dan Liang

1 State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, No. 54 Xianlie Road, Guangzhou 510060, China
2 458th Hospital of PLA, Guangzhou 510602, China

Correspondence should be addressed to Dan Liang; liangd2@mail.sysu.edu.cn

Received 1 May 2014; Revised 21 July 2014; Accepted 11 August 2014

Aim. To study the efficacy and safety of subantimicrobial dose (SD) doxycycline (50 mg/d) in patients with active and moderate-to-severe Graves’ orbitopathy (GO).

Methods. Thirteen patients with active and moderate-to-severe GO received once daily oral doxycycline (50 mg/d) for 12 wk. Treatment response at 24 wk was used as the primary outcome, measured by a composite of improvement in Clinical Activity Score (CAS), diplopia, motility, soft tissue swelling, proptosis, and eyelid aperture. Secondary outcome was the change of quality of life score (QoL, including visual functioning subscale and appearance subscale). Adverse events were also recorded.

Results. Overall improvement was noted in eight out of 13 patients (61.5%, 95% CI 31.6%–86.1%). Both CAS and soft tissue swelling significantly ameliorated in eight patients at 24 wk. Five patients (38.5%) had improvement in ocular motility of ≥ 8 degrees. Eyelid aperture (46.2%) also decreased remarkably. For QoL, a significant improvement in appearance subscale ($P = 0.008$) was noted during the study, whereas no difference was observed in visual functioning subscale ($P = 0.21$). Two patients reported mild stomachache at 12 wk.

Conclusions. SD doxycycline appears to be effective and safe for the treatment of active and moderate-to-severe GO. It might serve as a new promising therapeutic strategy for GO. This trial is registered with NCT01727973.

1. Introduction

Graves’ orbitopathy (GO) is a condition usually associated with autoimmune Graves’ disease (GD), and it might be caused by immunological cross-reactivity between thyroid and retrobulbar tissue autoantigens [1]. The natural history of GO varies greatly among patients. It can either progress or spontaneously regress, and a typical process can be divided into three phases: active (inflammatory) phase, stabilization, and remission (inactive) phase [2, 3]. The active phase can last for months or even years, and this has a profound impact on patients’ vision and quality of life. Therefore, the goal of treatment is to inactivate the autoimmune process. Immunosuppressive treatments are effective to arrest the active phase. So far, many immunosuppressive therapies have been reported, such as glucocorticoids (GCs), orbital radiotherapy, and cyclosporine, of which GCs represent the first-line treatment [4–6]. Oral GCs are successful in about 60% of patients with moderate-to-severe and active GO, but they often cause adverse events (81%) [7, 8]. Although intravenous (i.v.) GCs have a greater efficacy (around 80%) and adverse events are less common (39%), severe events (fatal acute liver failure and cardiovascular events) are more common [8, 9]. Other immunobiological therapies (e.g., rituximab) are currently under investigation and the efficacy and safety are not yet clearly presented [10, 11].

Doxycycline is known as a semisynthetic antibiotic. Independent of its antibiotic properties (200 mg/d), subantimicrobial dose (SD) doxycycline (40–50 mg/d; administered for a duration of 2 wk or 16 wk) displays a strong anti-inflammatory and immunomodulatory function [12, 13]. Data from clinical trials demonstrated that SD doxycycline was effective in moderating inflammation in a variety of autoimmune diseases, such as rheumatoid arthritis, multiple
sclerosis, rosacea, and periodontitis [14–16]. And few minor side effects (gastrointestinal events and photosensitivitv) were observed. The anti-inflammatory activities may be related to its ability of inhibiting many cytokine factors, including interleukin-1 (IL-1), tumor necrosis factor alpha (TNF-α), and matrix metalloproteases (MMPs), and of decreasing level of inflammatory cell infiltration and B lymphocyte proliferative responses [12, 17, 18]. Given that these cytokines and inflammatory responses are also seen among patients with active GO [1, 19, 20], SD doxycycline may serve as a treatment option. With this hypothesis, we investigated the efficacy and safety of SD doxycycline in patients with moderate-to-severe and active GO in the pilot study.

2. Patients and Methods

2.1. Patients and Study Design. From October 2012 to October 2013, consecutive patients aged 18 to 60 years, presenting with untreated active and moderate-to-severe GO, were recruited to participate in the study in Zhongshan Ophthalmic Center if they met inclusion criteria (see Supplementary Information in the Supplementary Material available online at http://dx.doi.org/10.1155/2015/285698). GO was diagnosed on the basis of typical features of the disease, such as eyelid retraction and swelling, proptosis, impaired motility, and enlarged extraocular muscles on orbital computed-tomography (CT) scans or magnetic resonance imaging (MRI) [7]. The severity and activity of GO were assessed according to the proposed criteria of the European Group on GO (EUGOGO) [21]. Patients had been euthyroid for a mean of 3 months before the date of inclusion.

All patients were treated on an outpatient basis and received 50 mg of doxycycline tablet once daily for 12 wk. We called patients every week to make sure that they took medicine exactly as ordered. Since euthyroidism was required for the study, antithyroid drugs (carbimazole, benzylthiouacil, and propylthiouracil) or levothyroxine was permitted throughout the study period, as long as the dosage was not significantly modified during the study. Also permitted were topical products (artificial tears and ocular lubricants).

The study was approved by the Institutional Review Board of Zhongshan Ophthalmic Center, Sun Yat-sen University, and conformed to the tenets of the Declaration of Helsinki. Written informed consent was obtained from all participants. It was registered on http://www.clinicaltrials.gov/ (NCT01727973).

2.2. Study Procedures. All patients were examined at baseline and 4, 12, and 24 wk after the start of treatment. A senior ophthalmologist with 20 yr experience of working on GO, who was masked to patients data, was asked to examine the patients throughout the study. Eye examinations were performed according to the Color Atlas evaluation (http://www.eugogo.eu/). At each visit, the subjective diplopia score was graded as no diplopia, intermittent, inconstant, and constant diplopia [22]. The eyelid aperture was measured as the distance in the midline between the eyelids, with the eyes in primary position. The lid lag was measured with a ruler as the distance between the limbus and lid margin in downgaze [23]. The soft tissue swelling was graded as no swelling, mild, moderate, or severe swelling [24]. Proptosis was measured using the same Marcus exophthalmometer and same intercanthal distance for each patient. Elevation, depression, adduction, and abduction of the individual eye were measured with a modified perimeter and recorded in degrees. BCVA was tested with a Snellen chart. The eye fundus was checked by fundoscopy. The activity of the disease was scored with the CAS. Finally, quality of life score (QoL), consisting of visual functioning subscale and appearance subscale, was evaluated with the Graves’ orbitopathy-specific quality of life (GO-QoL) questionnaire (http://www.eugogo.eu/).

2.3. Outcome Measurements. Considering that the natural course of GO usually has an active phase lasting for 6 to 18 months, we chose the treatment response at 24 wk as the primary outcome because the response would be expected within that time frame. As for the definition of treatment response, we referred to the major and minor criteria proposed by van Geest et al. [25, 26]. The treatment response was graded as follows: improvement, deterioration, and no success (see the Supplementary Information).

The secondary outcome included the changes of GO-QoL and adverse events. At each visit, details of all possible adverse events were collected. Patients were inquired about physical discomfort and the information was noted. Changes of blood pressure, body weight, and plasma concentrations of thyroid hormones were also recorded.

In addition, the quantitative changes of proptosis, eyelid aperture, lid lag, ocular motility, and CAS after treatment were recorded and compared with baseline.

2.4. Statistical Analysis. Analysis was performed using the “intention to treat” method. For example, patients withdrawn from the study prematurely for any reason were included in the final analysis if the evaluation at 4 wk visit was available. Results of their last assessment were carried forward and evaluated as the last visit. Patients lost to follow-up before the visit at 4 wk were excluded from the analysis.

Baseline characteristics of the patients were expressed as means (±SD) or numbers (proportions) or median (25th to 75th percentiles), as appropriate. For parameters expressed on a continuous scale, SAS PROC MIXED (SAS Institute Inc) with time modeled as a continuous variable was used to obtain the P-trend over 24 wk. Due to the discrete nature of the CAS, time trends during the trial were tested with a nonparametric approach (Jonckheere-Terpstra test). Mann-Whitney U test was used to compare the ophthalmological variables between baseline and 24 wk. All statistical tests were two-tailed, and $P < 0.05$ was considered statistically significant. All analyses were performed with the Statistical Analysis System (SAS) software package for windows, version 9.2 (SAS Institute Inc., Cary, NC).
3. Results

3.1. Patients. 68 patients (38 females and 30 males) with GO were referred for screening. Due to stringent inclusion and exclusion criteria, 20 patients were eligible and invited to participate in the study. Of these 20 patients, four declined to participate because of fear of the treatment or a wish to receive other treatments. The remaining 16 patients were administered 50 mg of doxycycline tablet daily for 12 weeks. Three patients dropped out because of immigration (one male) or lost to follow-up (two females) before the visit at 4 wk, and these three patients were not included in the final analysis. Out of the remaining 13 participants, 11 completed the study at 24 wk, while 2 patients finished the evaluation at 12 wk. Results of their last assessment were carried forward and evaluated as the last visit. The baseline characteristics of the subjects were shown in Table 1. The majority of patients were male (10/13 patients). Four patients had euthyroid Graves’ disease (4/13, 30.8%), and all of them were males.

3.2. Efficacy. Based on predefinition criteria, 12 wk doxycycline treatment led to successful response in eight out of 13 patients (61.5%, 95% CI 31.6%–86.1%) at the end of the trial. Deterioration occurred in two males at 12 wk, with worsening of soft tissue swelling. Both patients completed the evaluation at 12 wk and were subsequently treated with oral prednisone. No success was observed in the remaining three participants.

Table 2 showed the changes in individual variables. CAS significantly decreased during the trial ($P < 0.0001$). Two patients had a decrease of three points at 24 wk, and six patients had a two-point decrease. Soft tissue swelling also improved in eight out of 13 patients (61.5%) at 24 wk. A significant improvement was found when compared with baseline ($P = 0.044$). Interestingly, the majority of patients (9/13) reported that spontaneous orbital pain was relieved at 4 wk.

Only three patients (23.1%) reported improved diplopia at 24 wk: one from inconstant to no diplopia, one from intermittent to intermittent diplopia, and one from intermittent to no diplopia. Nevertheless, five patients (38.5%) had remarkable improvement in motility of ≥8 degrees at the end of trial. By investigating the motility at different directions in detail, we found that elevation, which represented the function of inferior rectus, significantly improved ($P = 0.0496$).

Proposis decreased in the minority of patients (2/13). No difference was observed compared with baseline. Both eyelid aperture (6/13, 46.2%) and lid lag (7/13, 53.8%) had substantial decrease at 24 wk. In particular, lid lag significantly decreased at 24 wk, compared with baseline ($P = 0.008$).

The mean scores on the GO-QoL questionnaire at baseline and after the intervention were also shown in Table 2. A significant improvement in appearance subscale ($P = 0.008$) was found during the study, whereas no difference was noted in visual functioning subscale ($P = 0.21$). The typical changes of appearance were demonstrated in Figure 1.

There were no differences measured throughout the study in any of the other parameters, including FT3, FT4, TSH, BCVA, corneal evaluation, and fundus examinations.

3.3. Adverse Events. SD doxycycline was well tolerated. No patients discontinued the study due to drug-related adverse events. Two patients reported mild stomachache at 12 wk, which disappeared when the treatment ended. No instances of vaginitis or photosensitivity were reported. Both body weight and blood pressure remained stable during the trial.

Table 1: Baseline characteristics of patients.

| Characteristic | Value |
|---------------|-------|
| Age (yr)      | 43.38 ± 11.82 |
| Gender (female) | 3 (23.1%) |
| Weight (kg)   | 68.08 ± 12.87 |
| Smoking history |        |
| Current smoker | 6 (46.2%) |
| Ex-smoker     | 1 (7.6%)  |
| Never-smoker  | 6 (46.2%) |
| History of thyroid disease |       |
| Graves’ hyperthyroidism | 9 (69.2%) |
| Euthyroid Graves’ disease | 4 (30.8%) |
| Others        | 0 (0%)    |
| Previous antithyroid treatments |       |
| Antithyroid drugs | 5 (55.6%) |
| Radioiodine   | 1 (11.1%) |
| Thyroidectomy | 3 (33.3%) |
| Duration of Graves’ disease (months) | 15 (6–24) |
| Duration of Graves’ orbitopathy (months) | 6 (3–12) |
| Duration of euthyroidism (months) | 3 (1.5–3.5) |
| Biochemical characteristics |       |
| FT3 (pmol/L)  | 5.02 (4.08–6.17) |
| FT4 (pmol/L)  | 14.32 (12.56–15.80) |
| TSH (mU/L)    | 0.54 (0.04–1.01) |
| Eye symptoms and signs |       |
| Proptosis (mm) | 21.19 ± 1.95 |
| Eyelid aperture (mm) | 12.31 ± 2.32 |
| Soft tissue involvements |       |
| Absent        | 0 (0%)    |
| Minimal       | 4 (30.8%) |
| Moderate      | 8 (61.5%) |
| Severe        | 1 (7.7%)  |
| Diplopia (Bahn and Gorman’s score) |       |
| Absent        | 3 (23.1%) |
| Intermittent  | 2 (15.4%) |
| Inconstant    | 3 (23.1%) |
| Constant      | 5 (38.4%) |
| Clinical Activity Score | 4 (3–5) |
| Ocular motility |        |
| Elevation (degrees) | 22.53 ± 13.07 |
| Depression (degrees) | 45.85 ± 15.97 |
| Adduction (degrees) | 41.62 ± 7.79 |
| Abduction (degrees) | 37.31 ± 11.40 |

FT3: free triiodothyronine; FT4: free thyroxine; TSH: thyrotropin.
Figure 1: Representative example of patients status at baseline and at 24 wk after the start of treatment. (a) (baseline) and (b) (24 wk) showed that soft tissue involvements and redness of conjunctiva were remarkably improved in a female at 24 wk. (c) (baseline) and (d) (24 wk) showed the improvement of eyelid aperture, lid lag, and elevation in a male treated by doxycycline.
Table 2: Eye signs, Clinical Activity Score, and Graves’ orbitopathy-specific quality of life (GO-QoL) score at baseline and at 12 and 24 wk evaluation.

| Variable                  | Baseline | Change at 12 wk | Change at 24 wk | P value, trend over time/baseline versus 24 wk |
|---------------------------|----------|-----------------|-----------------|---------------------------------------------|
| Proptosis (mm)            | 21.19 ± 1.95 | 0.04 (−0.6; 0.67) | −0.59 (−1.34; 0.16) | 0.26<sup>a</sup> |
| Improved (n, %)           | 2 (18.2%) | 2 (18.2%) |                     |                                             |
| Unchanged                 | 11 (81.8%) | 11 (81.8%) |                     |                                             |
| Deteriorated              | 0 (0%)   | 0 (0%) |                     |                                             |
| Eyelid aperture (mm)      | 12.31 ± 2.32 | −0.15 (−1.07; 0.76) | −1 (−2.24; 0.24) | 0.13<sup>a</sup> |
| Improved (n, %)           | 2 (15.4%) | 6 (46.2%) |                     |                                             |
| Unchanged                 | 9 (69.2%) | 5 (38.5%) |                     |                                             |
| Deteriorated              | 2 (15.4%) | 2 (15.4%) |                     |                                             |
| Lid lag (mm)              | 1.62 ± 1.94 | −0.54 (−1.54; 0.47) | −2.55 (−4.06; −1.03) | 0.008<sup>a</sup> |
| Improved (n, %)           | 5 (38.5%) | 7 (53.8%) |                     |                                             |
| Unchanged                 | 6 (46.2%) | 5 (38.5%) |                     |                                             |
| Deteriorated              | 2 (15.4%) | 1 (7.7%) |                     |                                             |
| Clinical Activity Score   | 4 (3–5)  | −1.07 ± 0.95    | −1.82 ± 0.87      | <0.0000<sup>b</sup> |
| Improved                  | 4 (30.8%) | 8 (61.5%) |                     |                                             |
| Unchanged                 | 9 (69.2%) | 5 (38.5%) |                     |                                             |
| Deteriorated              | 0 (0%)   | 0 (0%) |                     |                                             |
| Soft tissue signs (n, %)  |          |                 |                  | 0.044<sup>c</sup> |
| Absent                    | 0 (0%)   | 7 (53.8%) |                     |                                             |
| Minimal                   | 4 (30.8%) | 2 (15.4%) |                     |                                             |
| Moderate                  | 8 (61.5%) | 2 (15.4%) |                     |                                             |
| Severe                    | 1 (7.7%) | 2 (15.4%) |                     |                                             |
| Diplopia (n, %)           |          |                 |                  | 0.614<sup>c</sup> |
| Absent                    | 3 (23.1%) | 5 (38.5%) |                     |                                             |
| Intermittent              | 2 (15.4%) | 2 (15.4%) |                     |                                             |
| Inconstant                | 3 (23.1%) | 1 (7.7%) |                     |                                             |
| Constant                  | 5 (38.4%) | 5 (38.5%) |                     |                                             |
| Ocular motility           |          |                 |                  |                                             |
| Elevation (degrees)       | 22.54 ± 13.07 | 0.69 (−1.06; 2.44) | 4 (0.48; 7.52) | 0.0496<sup>a</sup> |
| Depression (degrees)      | 45.85 ± 15.97 | −0.38 (−2.95; 2.19) | −1.91 (−5.97; 2.15) | 0.35<sup>a</sup> |
| Adduction (degrees)       | 41.62 ± 7.79 | −1.64 (−4.10; 0.83) | −0.09 (−3.25; 3.07) | 0.78<sup>a</sup> |
| Abduction (degrees)       | 37.31 ± 11.40 | −1.00 (−4.17; 2.17) | −1.91 (−3.87; 0.05) | 0.14<sup>a</sup> |
| GO-QoL score              |          |                 |                  |                                             |
| Visual functioning score  | 61.99 ± 25.9 | 3.03 (−8.01; 14.07) | 9.65 (−0.28; 19.57) | 0.21<sup>a</sup> |
| Appearance score          | 46.17 ± 20.97 | 18.28 (7.77; 28.79) | 21.59 (5.83; 37.35) | 0.008<sup>a</sup> |

<sup>a</sup>These parameters were expressed on a continuous scale, and repeated-measures regression model was used to evaluate the 24 wk trend over time.

<sup>b</sup>This parameter was presented as median (25th to 75th percentiles), and a nonparametric approach (Jonckheere-Terpstra test) was adopted to assess the 24 wk trend over time.

<sup>c</sup>These parameters were presented as numbers, and Mann-Whitney U test was employed to compare the difference between baseline and 24 wk.

### 4. Discussion

This study is the first trial to evaluate the efficacy of SD doxycycline for patients with moderate-to-severe and active GO. An anti-inflammatory dose doxycycline (administered once daily (50 mg) for a duration of 12 wk) appeared to be effective and safe for the treatment of moderate-to-severe and active GO.

The success rate of those treated by SD doxycycline was 61.5% at the end of the trial. This was comparable to those treated by oral GCs (51–63%) or radiotherapy (60%) but lower than those treated by i.v. GCs (77–83%) [7, 8, 27]. Although i.v. GCs treatment yielded a greater efficacy, it was associated with severe adverse events, mostly consisting of fatal acute liver failure and cardiovascular events. In this study, the adverse events in those treated by doxycycline were mild and
the rate (15%) was significantly lower than those treated by i.v.
GCs (39%) or oral GCs (81%) [8].

It is worth noting that the proportion of patients with euthyroid Graves’ disease is much higher (4/13, 30.8%) com-
pared to data in the literature (19/221, 8.6%) [28]. Although
no clear explanation can be offered for this finding, one
possibility could be related to the sex distribution of patients.
A study by Marcocci et al. found that patients with euthyroid
Graves’ disease had a F/M ratio of 0.7, whereas ophthalmopa-
ythy associated with hyperthyroidism was significantly more
frequent in females, with a F/M ratio of 2.1 [28]. This indicates
a higher prevalence of euthyroid Graves’ disease in males.
We therefore consider that the high proportion of patients
with euthyroid Graves’ disease in our collective may be
explained by the high proportion of male patients recruited. It
is unusual that the majority of our patients are males (76.9%).
This is possibly due to the small number of eligible subjects
recruited, since more female patients had been referred for
screening. On the other hand, it confirms previous work that
male subjects show severe forms of GO [29,30]. Therefore,
we stand as a chance that this study may be
underpowered to detect the efficacy of doxycycline in treating
GO.

Soft tissue swelling and, particularly, CAS ameliorated
significantly at the end of the trial. 61.5% of patients showed
an improvement of soft tissue swelling and a decrease of CAS
by at least two points at 24 wk. The beneficial effect of SD
doxycycline on soft tissue swelling is similar to that on those
treated by GCs [7]. Moreover, nine out of 13 patients reported
that the spontaneous orbital pain (one point in theCAS)
diminished at the visit of 4 wk. These effects may be explained
by the rapid anti-inflammatory potential of SD doxycycline.
The rapid effect has also been found for rosacea, in which SD
doxycycline exerted a significant reduction of inflammatory
lesions within the first 3 weeks of therapy [13].

We also assessed several quantitative ocular parameters,
including proptosis, eyelid aperture, and lid lag. Although
proptosis showed minor change, both lid aperture and lid lag
had substantial improvement. In particular, lid lag decreased
remarkably in 53.8% of patients by at least 2 mm at the
end of the trial. Muller’s muscle hyperactivity was previously
considered to account for lid abnormality, on the basis of
excessive sympathetic activity of thyroid hormones [31].
Recently, Shih and his coworkers found a positive correlation
between macrophage count in the Muller’s muscle and severity
of upper lid retraction [32]. And they concluded that the
degree of inflammatory cells infiltration of Muller’s muscle
is associated with clinical severity of upper eyelid retraction
in GO. In the current study, all patients were euthyroid, and
improvement of CAS and eyelid swelling was also observed
in patients with a decrease of lid lag. We suggest that the
improvement of eyelid aperture and lid lag may be associated
with the amelioration of orbital inflammation by doxycycline.

Additionally, we found that doxycycline demonstrated an
effect in improving eye motility (5/13, 38.5%) by ≥8 degrees,
but insufficiently to influence the subjective diplopia score
(3/13, 23.1%). The efficacy observed in our study (38.5%) is
similar to those treated by oral GCs (42%) but weaker than
those treated by orbital radiotherapy (60%) [7]. The rationale
for radiotherapy in significantly improving motility resides in
both its nonspecific anti-inflammatory effects and inhibiting
orbital fibroblasts producing glycosaminoglycans, both of
which are the main actors in extraocular muscle dysfunction
[33]. Considering that SD doxycycline only possesses anti-
inflammatory activity, it is reasonable that the effect of
doxycycline in improving motility is lower than radiotherapy.

In this study, SD doxycycline also exerted a favorable
effect in improving quality of life, as assessed by the GO-
QoL questionnaire. The improvement was evident in the
appearance subscale but less obvious in the visual functioning
subscale. This may be attributed to the amelioration of soft
tissue swelling and decreased lid fissure, which reflect the
changes of appearance. In contrast, visual acuity remained
stable during the trial, and improved diplopia was only
reported in 23.1% of patients. These two factors dominantly
contribute to the visual function. Hence, it is reasonable that
the visual functioning subscale was less affected.

Of note, adverse events associated with SD doxycycline
are rare. Only two patients reported mild stomachache at
12 wk, not requiring additional medication. No patient com-
plained about photosensitivity or vaginitis. These findings
are in line with previous studies for patients with rosacea
and periodontitis [34, 35]. By extensive investigations of the
oral, gastrointestinal, genitourinary, and skin microflora of
patients receiving SD doxycycline for 6 to 18 months, no
reduction in the microflora was observed, and no devel-
oment of resistant organisms was found [36, 37]. Unlike
GCs, which frequently lead to weight gain and hypertension,
SD doxycycline did not impact weight and blood pressure.
Taken together, the minor side effect of SD doxycycline
highlights its good tolerability in long-term usage. According
to previous studies, the most common dose of subantimicro-
bial doxycycline used as anti-inflammatory agent is 40 mg
(20 mg per tablet) [38]. Since the formulation of 20 mg for
doxycycline is unavailable in China, we adopted the common
formulation of 50 mg, administered once daily. The long half-
life of doxycycline permits once-daily dosing. Still, it turned
out that the side effects were minor.

We must acknowledge that this study bears the limitation
of being an uncontrolled trial. To minimize the bias, a senior
ophthalmologist, who was masked to patients data, per-
formed the examination throughout the study. Considering
that the clinical assessments and outcome measurements
were objective and were largely consistent with those intro-
duced by prior studies [5, 25, 27], we think the findings
are representative. A multicenter, double-blind, randomized,
and controlled trial (doxycycline versus GCs) is urgently needed
to confirm its effect. Such kind of study is in progress in
China, led by our group.

5. Conclusion

Subantimicrobial dose doxycycline appears to be effective
and safe in treating active Graves’ orbitopathy. This finding
may suggest a new promising therapeutic agent for active GO.
Conflict of Interests
The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution
Miaoli Lin and Yuxiang Mao contributed equally to the paper.

Acknowledgments
This project was supported by Grants from Sun Yat-Sen University Clinical Research 5010 Program (2012015), Science and Technology Program of Guangdong Province 5511B061700085, and Science and Technology Program of Guangzhou (11BPP2Xaa2060017). The sponsor or funding organization had no role in designing or conducting this research.

References
[1] R. S. Douglas and S. Gupta, “The pathophysiology of thyroid eye disease: implications for immunotherapy,” Current Opinion in Ophthalmology, vol. 22, no. 5, pp. 385–390, 2011.
[2] E. Piantanida, M. L. Tanda, A. Lai, L. Sassi, and L. Bartalena, “Prevalence and natural history of Graves’ orbitopathy in the XXI century,” Journal of Endocrinological Investigation, vol. 36, no. 6, pp. 444–449, 2013.
[3] M. L. Tanda, E. Piantanida, L. Liparulo et al., “Prevalence and natural history of graves’ orbitopathy in a large series of patients with newly diagnosed graves’ hyperthyroidism seen at a single center,” The Journal of Clinical Endocrinology & Metabolism, vol. 98, no. 4, pp. 1443–1449, 2013.
[4] G. J. Kahaly, S. Pitz, G. Hommel, and M. Dittmar, “Randomized, single blind trial of intravenous versus oral steroid monotherapy in graves’ orbitopathy,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 9, pp. 5234–5240, 2005.
[5] L. Bartalena, G. E. Krassas, W. Wiersinga et al., “Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves’ orbitopathy,” The Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 12, pp. 4454–4463, 2012.
[6] S. Zang, K. A. Ponto, and G. J. Kahaly, “Intravenous glucocorticoids for graves’ orbitopathy: efficacy and morbidity,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 2, pp. 320–332, 2011.
[7] M. F. Prummel, M. P. Mourits, L. Blank, A. Berghout, L. Koornneef, and W. M. Wiersinga, “Randomised double-blind trial of prednisone versus radiotherapy in Graves’ ophthalmopathy,” The Lancet, vol. 342, no. 8877, pp. 949–954, 1993.
[8] C. Marcocci, T. Watt, M. A. Altea et al., “Fatal and non-fatal adverse events of glucocorticoid therapy for Graves’ orbitopathy: a questionnaire survey among members of the European Thyroid Association,” European Journal of Endocrinology, vol. 166, no. 2, pp. 247–253, 2012.
[9] S. Zangi, K. A. Ponto, S. Pitz, and G. J. Kahaly, “Dose of intravenous steroids and therapy outcome in Graves’ orbitopathy,” Journal of Endocrinological Investigation, vol. 34, no. 11, pp. 876–880, 2011.
[10] D. Khanna, K. K. L. Chong, N. F. Afifiyan et al., “Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy,” Ophthalmology, vol. 117, no. 1, pp. 133.e2–139.e2, 2010.
[11] G. Vannucchi, I. Campi, M. Bonomi et al., “Rituximab treatment in patients with active Graves’ orbitopathy: effects on proinflammatory and humoral immune reactions,” Clinical and Experimental Immunology, vol. 161, no. 3, pp. 436–443, 2010.
[12] J. H. N. Lindeman, H. Abdul-Hussien, J. H. Van Bockel, R. Wolterbeek, and R. Kleemann, “Clinical trial of doxycycline for matrix metalloproteinase-9 inhibition in patients with an abdominal aneurism doxycycline selectively depletes aortic wall neutrophils and cytotoxic t cells,” Circulation, vol. 119, no. 16, pp. 2209–2216, 2009.
[13] J. Q. del Rosso, G. F. Webster, M. Jackson et al., “Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea,” Journal of the American Academy of Dermatology, vol. 56, no. 5, pp. 791–802, 2007.
[14] L. M. Golub, M. L. Hsi, J. A. Stoner et al., “Subantimicrobial-dose doxycycline modulates gingival crevicular fluid biomarkers of periodontitis in postmenopausal osteopenic women,” Journal of Periodontology, vol. 79, no. 8, pp. 1409–1418, 2008.
[15] A. Minagar, J. S. Alexander, R. N. Schwendimann et al., “Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial,” Archives of Neurology, vol. 65, no. 2, pp. 199–204, 2008.
[16] J. R. O’Dell, J. R. Elliott, J. A. Mallek et al., “Treatment of early seropositive rheumatoid arthritis: doxycycline plus methotrexate versus methotrexate alone,” Arthritis and Rheumatism, vol. 54, no. 2, pp. 621–627, 2006.
[17] N. Bostanci, B. Akgül, V. Tsakanika, R. P. Allaker, F. J. Hughes, and I. J. McKay, “Effects of low-dose doxycycline on cytokine secretion in human monocytes stimulated with Aggregatibacter actinomycetemcomitans,” Cytokine, vol. 56, no. 3, pp. 656–661, 2011.
[18] G. Emingil, A. Gürkan, G. Atilla, and A. Kantarci, “Subantimicrobial-dose doxycycline and cytokine-chemokine levels in gingival crevicular fluid,” Journal of Periodontology, vol. 82, no. 3, pp. 452–461, 2011.
[19] R. S. Bahn, “Graves’ ophthalmopathy,” The New England Journal of Medicine, vol. 362, no. 8, pp. 726–774, 2010.
[20] T. J. Smith, “Pathogenesis of Graves’ orbitopathy: a 2010 update,” Journal of Endocrinological Investigation, vol. 33, no. 6, pp. 414–421, 2010.
[21] L. Bartalena, L. Balodeschi, A. Dickinson et al., “Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO,” European Journal of Endocrinology, vol. 158, no. 3, pp. 273–285, 2008.
[22] R. S. Bahn and C. A. Gorman, “Choice of therapy and criteria for assessing treatment outcome in thyroid-associated ophthalmopathy,” Endocrinology and Metabolism Clinics of North America, vol. 16, no. 2, pp. 391–407, 1987.
[23] E. S. Hallin and S. E. Feldon, “Graves’ ophthalmopathy: II. Correlation of clinical signs with measures derived from computed tomography,” The British Journal of Ophthalmology, vol. 72, no. 9, pp. 678–682, 1988.
[24] A. J. Dickinson and P. Perros, “Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment,” Clinical Endocrinology, vol. 55, no. 3, pp. 283–303, 2001.
[25] R. J. van Geest, I. V. Sasim, H. P. F. Koppeschaar et al., "Methylprednisolone pulse therapy for patients with moderately severe Graves' orbitopathy: a prospective, randomized, placebo-controlled study," *European Journal of Endocrinology*, vol. 158, no. 2, pp. 229–237, 2008.

[26] L. Bartalena, C. Marcocci, F. Bogazzi et al., "Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy," *The New England Journal of Medicine*, vol. 338, no. 2, pp. 73–78, 1998.

[27] M. P. Mourits, M. L. Van Kempen-Hartevelt, M. B. García García, H. P. F. Koppeschaar, L. Tick, and C. B. Terwee, "Radiotherapy for Graves' orbitopathy: randomised placebo-controlled study," *Lancet*, vol. 355, no. 9214, pp. 1505–1509, 2000.

[28] C. Marcocci, L. Bartalena, F. Bogazzi, M. Panicucci, and A. Pinchera, "Studies on the occurrence of ophthalmopathy in Graves' disease," *Acta Endocrinologica*, vol. 120, no. 4, pp. 473–478, 1989.

[29] P. Perros, A. L. Croome, J. N. S. Matthews, and P. Kendall-Taylor, "Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic," *Clinical Endocrinology*, vol. 38, no. 4, pp. 367–372, 1993.

[30] L. Bartalena, A. Pinchera, and C. Marcocci, "Management of Graves' ophthalmopathy: reality and perspectives," *Endocrine Reviews*, vol. 21, no. 2, pp. 168–199, 2000.

[31] G. J. Ben Simon, A. M. Mansury, R. M. Schwarz, S. Modjtahedi, J. D. McCann, and R. A. Goldberg, "Transconjunctival Müller muscle recession with levator disinsertion for correction of eyelid retraction associated with thyroid-related orbitopathy," *The American Journal of Ophthalmology*, vol. 140, no. 1, pp. 94.e1–94.e7, 2005.

[32] M. Shih, S. Liao, K. Kuo, T. J. Smith, and L. Chuang, "Molecular pathology of Müller's muscle in Graves' ophthalmopathy," *The Journal of Clinical Endocrinology and Metabolism*, vol. 91, no. 3, pp. 1159–1167, 2006.

[33] M. L. Tanda and L. Bartalena, "Efficacy and safety of orbital radiotherapy for Graves' orbitopathy," *Journal of Clinical Endocrinology and Metabolism*, vol. 97, no. 11, pp. 3857–3865, 2012.

[34] C. Walker, P. M. Preshaw, J. Novak, A. F. Hefti, M. Bradshaw, and C. Powala, "Long-term treatment with sub-antimicrobial dose doxycycline has no antibacterial effect on intestinal flora," *Journal of Clinical Periodontology*, vol. 32, no. 11, pp. 1163–1169, 2005.

[35] E. Monk, A. Shalita, and D. M. Siegel, "Clinical applications of non-antimicrobial tetracyclines in dermatology," *Pharmacological Research*, vol. 63, no. 2, pp. 130–135, 2011.

[36] M. U. Rashid, G. Panagiotidis, T. Backström, A. Weintraub, and C. E. Nord, "Ecological impact of doxycycline at low dose on normal oropharyngeal and intestinal microflora," *International Journal of Antimicrobial Agents*, vol. 41, no. 4, pp. 352–357, 2013.

[37] C. Walker, S. Puumala, L. M. Golub et al., "Subantimicrobial dose doxycycline effects on osteopenic bone loss: microbiologic results," *Journal of Periodontology*, vol. 78, no. 8, pp. 1590–1601, 2007.

[38] Y. Gu, C. Walker, M. E. Ryan, J. B. Payne, and L. M. Golub, "Non-antibacterial tetracycline formulations: clinical applications in dentistry and medicine," *Journal of Oral Microbiology*, vol. 4, Article ID 19227, 2012.